MTE #30 Viral Reactivation After Immunosuppressive Therapy (Ticketed) | AASLD

MTE #30 Viral Reactivation After Immunosuppressive Therapy (Ticketed)

Nov 10 2025
Convention Center: Room 140B, Level 1
7:00 AM - 7:45 AM
Ticketed Event

World Class Speakers

Harrys A Torres, MD, FAASLD
Discussion Leader

Harrys A Torres, MD, FAASLD

The University of Texas MD Anderson Cancer Center
Robert Gish, MD
Discussion Leader

Robert Gish, MD

Robert G Gish Consultants LLC

Description

Experts provide an update on HBV, HCV, and HEV infections in immunocompromised patients, focusing on viral reactivation after immunosuppressive treatment. Topics include: various types reactivation of viral hepatitis; at-risk patient populations; diagnostic criteria for reactivation of HBV, HCV, and HEV infection; preventive measures; effects of specific immunosuppressive therapies; and timing of antiviral treatment. 

 

Journey Maps

Objectives

  • Describe and contrast the various types of reactivation of viral hepatitis and the different patient populations that are at risk.
  • Review and discuss the diagnostic criteria for reactivation of HBV, HCV, and HEV.
  • Discuss preventive measures, the effects of specific immunosuppressive therapies, benefits, and the timing of antiviral treatment for patients experiencing reactivation of viral hepatitis.